AbCellera (ABCL)

Executive Summary

AbCellera is a Vancouver-based biotechnology company that leverages an AI-powered microfluidics and machine learning platform to discover antibody therapeutics at unprecedented scale. The company operates as a technology enabler, identifying therapeutic antibodies rapidly across multiple therapeutic areas including women's health, immunology, autoimmunity, and oncology. Listed on NASDAQ (ABCL), AbCellera has built a robust discovery engine that partners with pharmaceutical companies and also advances its own internal pipeline. The company's platform aims to reduce the time and cost of antibody discovery, positioning it as a key player in the next generation of biologic drug development. AbCellera's current pipeline includes two clinical-stage programs: ABCL635 in Phase 1/2 for vasomotor symptoms associated with menopause (NCT07118891, estimated completion February 2027) and ABCL575 in Phase 1 for healthy volunteers (NCT07108894, estimated completion April 2027). These programs represent the company's move towards internal product development beyond its partnership model. Upcoming catalysts include interim data readouts from these trials, which could validate the platform's ability to generate differentiated antibodies. The company's conviction score reflects its early stage but promising platform, with key near-term milestones that could significantly impact valuation.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 interim data for ABCL635 in vasomotor symptoms60% success
• Q4 2026Phase 1 safety data for ABCL575 in healthy volunteers70% success
• TBDPotential new partnership or licensing deal50% success